Wiczling P - Search Results

1

Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations.

Krzyzanski W, Wiczling P, Lowe P, Pigeolet E, Fink M, Berghout A, Balser S. Krzyzanski W, et al. Among authors: wiczling p. J Clin Pharmacol. 2010 Sep;50(9 Suppl):101S-112S. doi: 10.1177/0091270010376966. J Clin Pharmacol. 2010. PMID: 20881223

2

Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model.

Wiczling P, Krzyzanski W. Wiczling P, et al. Cytometry A. 2007 Jul;71(7):460-7. doi: 10.1002/cyto.a.20408. Cytometry A. 2007. PMID: 17458910 Free article.

3

Flow cytometric assessment of homeostatic aging of reticulocytes in rats.

Wiczling P, Krzyzanski W. Wiczling P, et al. Exp Hematol. 2008 Feb;36(2):119-27. doi: 10.1016/j.exphem.2007.09.002. Exp Hematol. 2008. PMID: 18206724 Free article.

4

Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats.

Wiczling P, Ait-Oudhia S, Krzyzanski W. Wiczling P, et al. Cytometry A. 2009 Jul;75(7):584-92. doi: 10.1002/cyto.a.20736. Cytometry A. 2009. PMID: 19437531 Free article.

5

Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.

Wiczling P, Lowe P, Pigeolet E, Lüdicke F, Balser S, Krzyzanski W. Wiczling P, et al. Clin Pharmacokinet. 2009;48(12):817-26. doi: 10.2165/11318090-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19902989

6

Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus.

Wiczling P, Rosenzweig M, Vaickus L, Jusko WJ. Wiczling P, et al. J Clin Pharmacol. 2010 May;50(5):494-506. doi: 10.1177/0091270009349376. Epub 2009 Nov 23. J Clin Pharmacol. 2010. PMID: 19934031

7

The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats.

Wiczling P, Krzyzanski W, Zychlińska N, Lewandowski K, Kaliszan R. Wiczling P, et al. Biopharm Drug Dispos. 2014 Sep;35(6):330-40. doi: 10.1002/bdd.1902. Epub 2014 Jun 27. Biopharm Drug Dispos. 2014. PMID: 24888906

8

Age-structured population model of cell survival.

Krzyzanski W, Wiczling P, Gebre A. Krzyzanski W, et al. Among authors: wiczling p. J Pharmacokinet Pharmacodyn. 2017 Aug;44(4):305-316. doi: 10.1007/s10928-017-9520-6. Epub 2017 Mar 29. J Pharmacokinet Pharmacodyn. 2017. PMID: 28357630

9

Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients.

Smuszkiewicz P, Wiczling P, Ber J, Warzybok J, Małkiewicz T, Matysiak J, Klupczyńska A, Trojanowska I, Kokot Z, Grześkowiak E, Krzyzanski W, Bienert A. Smuszkiewicz P, et al. Among authors: wiczling p. J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):277-284. doi: 10.1007/s10928-017-9564-7. Epub 2017 Dec 30. J Pharmacokinet Pharmacodyn. 2018. PMID: 29290034 Free PMC article.

10

Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats.

Nguyen LM, Singh AP, Wiczling P, Krzyzanski W. Nguyen LM, et al. Among authors: wiczling p. Front Pharmacol. 2018 Apr 10;9:316. doi: 10.3389/fphar.2018.00316. eCollection 2018. Front Pharmacol. 2018. PMID: 29692726 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page